Kardigan, Inc.

Kardigan, Inc. (KARD) priced its initial public offering on Jun 18, 2026 at $16.00 per share, raising $400M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.43B. J.P. Morgan was lead-left underwriter, joined by Jefferies, Leerink Partners and TD Cowen. Latham & Watkins advised the underwriters.

Kardigan, Inc. is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases with no approved treatments. It was formed in August 2023 as EnCarda, Inc.

Status

IPO

Ticker

KARD

Exchange

Nasdaq Global Market

Priced

Jun 18, 2026

IPO price

$16.00

Raised

$400M

Market cap at IPO price

$1.43B

First filed

May 26, 2026

Underwriters

J.P. Morgan, Jefferies, Leerink Partners and TD Cowen

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.